Comment from Foley and Lardner LLP

Summary: LNK International, Inc., a manufacturer of generic over-the-counter pharmaceuticals, opposes the petition requesting that the FDA reflect potential neurodevelopmental risks from acetaminophen. The company argues that the petition lacks scientific consensus, that the current monograph is the safest and most appropriate for consumers, and that any changes must follow the specific legal procedures established by the CARES Act.